Sept. 23 (UPI) -- Indianapolis-based Eli Lilly intends to build a biomanufacturing facility that would cost $6.5 billion to build and employ 4,000 construction workers in the greater Houston area.
Construction of the 236-acre facility would begin before the end of this year and conclude within five years the pharmaceutical manufacturer announced on Tuesday, according to the Houston Chronicle.
"Our new Houston site will. Enhance Lilly's ability to manufacture orforglipron at scale and, if approved, help fulfill the medicine's potential as a metabolic health treatment for tens of millions of people who prefer the ease of a pill that can be taken without food or water restrictions," Eli Lilly Chief Executive Officer David Ricks said in a prepared statement.
"This significant U.S. investment and onshoring of our API (active pharmaceutical ingredient) production capabilities will ensure faster, more secure access to orforglipron and to other life-changing medicines of the future."
Related
